J&J Not Sweating Remicade Biosimilar Approval
The company remains comfortable with the growth outlook for pharmaceuticals despite FDA approval of a rival biosimilar to its blockbuster Remicade, the firm said during its first quarter conference call.
The company remains comfortable with the growth outlook for pharmaceuticals despite FDA approval of a rival biosimilar to its blockbuster Remicade, the firm said during its first quarter conference call.